

## Inflazyme Pharmaceuticals Ltd.

[View the current Inflazyme Pharmaceuticals Ltd. Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/11302-Inflazyme+Pharmaceuticals+Ltd..html)

(<http://www.bioportfolio.com/bioporporate/11302-Inflazyme+Pharmaceuticals+Ltd..html>)

### Contact Details:

**Suite 425, 5600 Parkwood Way  
Richmond  
British Columbia  
V6V 2M2  
Canada**

Tel: (604) 279-8511  
Fax: (604) 279-8711  
Email: [info@inflazyme.com](mailto:info@inflazyme.com)

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of respiratory and inflammatory diseases. Our core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Our most advanced product, IPL512,602, is on track to enter a phase IIb clinical study by Q1'06 for the treatment of persistent asthma. Our second product, IPL455,903 (also known as HT0712), is scheduled to enter a Phase IIa clinical study by Q1'06. The product is partnered with Helicon Therapeutics, Inc., a biotechnology company specializing in learning and memory disorders.

### Recent Publications by Inflazyme Pharmaceuticals Ltd.:



- [IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge.](#)  
*IPL576,092, a lead compound from a novel class of polyhydroxylated...*9th March, 2005  
Inflazyme Pharmaceuticals Ltd, 425-5600 Parkwood Way, Richmond, BC, Canada- *Pulm Pharmacol Ther.* 2004;17(5):309-18. ([DOI Direct Link](#))
- [Efficient synthesis of IPL576,092: a novel anti-asthma agent.](#)  
*An enantioselective synthesis of the novel anti-asthma agent IRL576,092 (2)...*26th November, 2002  
Inflazyme Pharmaceuticals Ltd., Suite 425, 5600 Parkwood Way, Richmond,- *J Org Chem.* 2002 May 31;67(11):3908-10.

**Press Releases on Inflazyme Pharmaceuticals Ltd.:**

<a href="#">Reportlinker Adds Imaging Agents - A Worldwide Market Review</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review <a href="http://www.reportlinker.com">http://www.reportlinker.com</a>
<a href="#">AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured</a>	20th November, 2009	AstraZeneca	WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6
<a href="#">Impax Laboratories Drives Stronger Performance with IBM Business Analytics</a>	20th November, 2009	IBM	-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether
<a href="#">Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference</a>	19th November, 2009	Alexza Pharmaceuticals, Inc.	MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 21st Annual Piper
<a href="#">AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season</a>	19th November, 2009	Medialink	NEW YORK, Nov. 19 /PRNewswire/ -- As the seasons change, another season of coughs and running noses is here. Here's more on preparing yourself. Listen to this report from Ortho-McNeil-Janssen

**BioNews Results for Inflazyme Pharmaceuticals Ltd.**



- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)  
*FinanzNachrichten.de: Nov 16 2009 12:34AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to](#)

[Discuss Resu](#)

*Dallas Business Chronicle: Nov 16 2009 3:33AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Kansas City Business Journal: Nov 16 2009 3:25AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*South Florida Business Journal: Nov 16 2009 3:23AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Washington Business Journal: Nov 16 2009 1:25AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*St Louis Business Journal: Nov 16 2009 12:45AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*San Jose Business Journal: Nov 16 2009 12:35AM Matching: pharmaceuticals*

- [BioSante Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)

*PR inside: Nov 16 2009 4:03AM Matching: pharmaceuticals*

- [Alnylam Pharmaceuticals Down 19.9% Since SmarTrend's Sell Recommendation](#)

*TradingMarkets: Nov 16 2009 4:21AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Reuters: Nov 16 2009 12:43AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Globe Investor: Nov 16 2009 12:36AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*StockHouse USA: Nov 16 2009 12:22AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*TradingMarkets: Nov 16 2009 12:18AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)

*Stockwatch: Nov 16 2009 12:15AM Matching: pharmaceuticals*

- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)

*Pharmacy Choice: Nov 15 2009 2:33PM Matching: pharmaceuticals*

**Inflazyme Pharmaceuticals Ltd. Patents:**



- 7112580- [3-nitrogen-6, 7-dioxygen steroids and uses related thereto](#)

- 6046185- [6,7-oxygenated steroids and uses related thereto](#)
- 6458829- [Substituted .gamma.-phenyl-.DELTA.-lactones and analogs thereof and uses related thereto](#)
- 6555572- [Benzylated PDE4 inhibitors](#)
- 6635629- [3-nitrogen-6,7-dioxygen steroids and uses related thereto](#)
- 6696580- [Process for the production of 6,7-diols of steroidal compounds](#)
- 6706701- [6, 7-oxygenated steroids and uses related thereto](#)
- 6770658- [Substituted .gamma.-phenyl-.DELTA.-lactams and uses related thereto](#)
- 6949533- [6,7-Oxygenated steroids and uses related thereto](#)
- 6982329- [Process improvements in steroid chemistry](#)
- 7067682- [6,7-Oxygenated steroids and uses related thereto](#)
- 5399683- [Mirror amide cord factors and mirror thioester cord factors for diagnosis of tuberculosis](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

